Evaluating safety of long-acting beta agonists (labas) in patients with asthma

Current Drug Safety

Volumn 5, Issue 3, 2010, Pages 245-250

  Bian, Boyang ^a   Kelton, Christina M L ^b   Wigle, Patricia R ^a   Guo, Jeff J ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

African americans; Asthma; Long acting beta agonists (labas); Pediatric laba use; Safety controversy; Smart trial

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; LEVALBUTEROL; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; ORAPRED; PLACEBO; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL XINAFOATE; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION;

ARTICLE; ASTHMA; CLINICAL TRIAL; DEATH; DISEASE EXACERBATION; DRUG SAFETY; DRUG USE; EMERGENCY WARD; EVALUATION; HEALTH VISITOR; HOSPITALIZATION; HUMAN; INTUBATION; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; PATHOPHYSIOLOGY; QUALITY OF LIFE; UNITED STATES;

ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUG LABELING; HUMANS; QUALITY OF LIFE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954686490     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610791698316     Document Type: Article

References (23)

1. American Lung Association, Trends in asthma morbidity and mortality, January 2009. Available at: http://www.lungusa.org/find ing-cures/for-professionals/epidemiology-and-statistics-rpts.html. Accessed on January 29, 2010.
2. National Heat, Lung, and Blood institute. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma (Expert Panel Review-3). August 28, 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asth gdln.pdf Accessed on January 29, 2010.
3. Food and Drug Administration. Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm. Accessed on January 29, 2010.
4. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24 hour spirometry and Holter monitoring. Ann Allergy 1993; 70: 316-22.
5. Derom EY, Pauwels RA, Van der Straeten ME. The effect of inhaled salmeterol on methacholine responsiveness in patients with asthma up to 12 h. J Allergy Clin Immunol 1992; 89: 811-5.
6. Boyd G, Morice AH, Pousford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10: 815-g21.
7. Clinical Pharmacology. Available at: http://www.clinicalpharmaco logy-ip.com/Default.aspx. Accessed on January 30, 2009.
8. Aaronson D. The "black box" warning and allergy drugs. J Allergy Clin Immunol 2006; 117: 40-4.
9. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993; 306: 1034-7.
10. Nelson H, Weiss S, Bleecker E, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
11. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178(10): 1009-16.
12. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2- agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583-93.
13. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta- analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med 2006;144: 904-12.
14. Rodrigo G, Moral V, Marcos L, Castro-Rodriguez J. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: A systematic review. Pulm Pharmacol Ther 2009; 22(1): 9-19.
15. Bisgaard H. Effect of long-acting 2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003; 36: 391-8.
16. Food and Drug Administration. Diskus, and Symbicort information (long acting beta agonists). Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvi ders/ucm108111.htm. Accessed on January 30, 2010.
17. Food and Drug Administration. FDA Advisory Committee Meeting on the safety of long acting beta2-agonists for the treatment of asthma in adults and children. Available at: http://www.fda.gov/ ohrms/dockets/ac/08/briefing/2008-4398b1-02-Novartis.pdf. Assessed on January 30, 2010.
18. Lozano P, Connell FA, and Koepsell TD. Use of health services by African-American children with asthma on Medicaid. JAMA 1995; 274: 469-73.
19. Zoratti EM, Havstad S, Rodriguez J, et al. Health care service use by African-Americans and Caucasians with asthma in a managed care setting. Am J Respir Crit Care Med 1998;158: 371-7.
20. Johnson M. Molecular mechanisms of _2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117: 18-24.
21. Wechsler M, and Israel E. How pharmacogenetics will play a role in the management of asthma. Am J Respir Crit Care Med 2005; 172: 12-8.
22. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta- 2-adrenergic receptor polymorphism on response to longacting beta-2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled crossover trial. Lancet 2009: 1754-64.
23. Reddy P, Aksoy M, Yang Y, Li X, Ji R, Kelsen S. Inhibition by Salmeterol and Cilomilast of Fluticasone-Enhanced IP-10 Release in Airway Epithelial Cells. COPD: J Chronic Obstr Pulmonary Dis [serial online]. 2008; 5(1): 5-11.